Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.

Colson P, Bregigeon S, Tourres C, Solas C, Poizot-Martin I, Tamalet C.

J Clin Virol. 2013 Sep;58(1):309-14. doi: 10.1016/j.jcv.2013.05.009. Epub 2013 Jun 28.

PMID:
23810614
2.

Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.

Soriano V, Núñez M, Camino N, Maida I, Barreiro P, Romero M, Martin-Carbonero L, Garcia-Samaniego J, González-Lahoz J.

Antivir Ther. 2004 Aug;9(4):505-9.

PMID:
15456081
3.

Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.

Bolcic F, Sede M, Moretti F, Westergaard G, Vazquez M, Laufer N, Quarleri J.

Arch Virol. 2012 Apr;157(4):703-11. doi: 10.1007/s00705-012-1230-1. Epub 2012 Jan 22.

PMID:
22270759
4.

Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.

Ioannou GN, Scott JD, Yang Y, Green PK, Beste LA.

Aliment Pharmacol Ther. 2013 Dec;38(11-12):1373-84. doi: 10.1111/apt.12524. Epub 2013 Oct 16.

5.

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.

Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, Zeuzem S, Pape GR, Hopf U.

Liver. 2000 Dec;20(6):427-36.

PMID:
11169056
6.

Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.

Giannini EG, Basso M, Savarino V, Picciotto A.

Aliment Pharmacol Ther. 2010 Feb 15;31(4):502-8. doi: 10.1111/j.1365-2036.2009.04201.x. Epub 2009 Nov 19.

7.

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.

Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Bréchot C, Pol S.

Gut. 2000 Nov;47(5):694-7.

8.

Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.

Hasson H, Messina E, Merli M, Della Torre L, Morsica G, Bagaglio S, Lazzarin A, Uberti-Foppa C.

Int J Infect Dis. 2014 Dec;29:100-2. doi: 10.1016/j.ijid.2014.08.011. Epub 2014 Oct 24.

9.

Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.

Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Tsai SL, Kuo HT.

Transl Res. 2006 Sep;148(3):120-7.

PMID:
16938649
10.

New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.

Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y.

J Med Virol. 2013 Sep;85(9):1523-33. doi: 10.1002/jmv.23626. Epub 2013 Jun 17.

PMID:
23775277
11.

[Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin].

Li QR, Zhang CJ, Xiong YL, Zhu Y, Tan ZX, Hu YJ, Yuan J, Wang XH.

Zhonghua Gan Zang Bing Za Zhi. 2012 May;20(5):353-6. doi: 10.3760/cma.j.issn.1007-3418.2012.05.010. Chinese.

PMID:
22971280
12.

Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.

Soriano V, Núñez M, Sánchez-Conde M, Barreiro P, García-Samaniego J, Martín-Carbonero L, Romero M, González-Lahoz J.

Antivir Ther. 2005;10(1):167-70.

PMID:
15751774
13.

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.

Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J; GESIDA3603/5607 Study Group.

Hepatology. 2009 Aug;50(2):407-13. doi: 10.1002/hep.23020.

PMID:
19575364
14.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
15.
16.

Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.

Chary A, Winters MA, Kottilil S, Murphy AA, Polis MA, Holodniy M.

J Infect Dis. 2010 Sep 15;202(6):889-93. doi: 10.1086/655784.

17.

Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy.

Chen MH, Chen MH, Tsai CY, Chou CT, Lin HY, Huang DF, Huang YH.

Lupus. 2015 Sep;24(10):1029-36. doi: 10.1177/0961203315571465. Epub 2015 Feb 16.

PMID:
25691509
18.

Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy.

Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, Viard JP, Piketty C, Rouveix E, Rouzioux C, Weiss L, Pol S.

AIDS. 2006 Jan 9;20(2):233-40.

PMID:
16511416
19.

Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients.

Nevot M, Boesecke C, Parera M, Andrés C, Franco S, Revollo B, Ingiliz P, Tural C, Clotet B, Rockstroh JK, Martinez MA; NEAT study group.

J Viral Hepat. 2014 Jun;21(6):e19-28. doi: 10.1111/jvh.12254. Epub 2014 Mar 27.

PMID:
24674023
20.

Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.

Soriano V, Pérez-Olmeda M, Ríos P, Núñez M, García-Samaniego J, González-Lahoz J.

AIDS Res Hum Retroviruses. 2004 Apr;20(4):351-3.

PMID:
15157353

Supplemental Content

Support Center